The Process Improvement Team at the University of Miami Health System is a group of professionals with backgrounds in Lean, Six Sigma and project management. “We exist to continually improve the patient, faculty and staff experience by leading transformative projects and supporting system-wide improvement initiatives,” said Brianne Neuburger, senior project manager in the Office of Process Improvement.
An NIH-funded study by researchers at the University of Miami Miller School of Medicine has found that topical treatment with mevastatin will block two common healing inhibitors in diabetic foot ulcers, a life-threatening complication of diabetes mellitus with limited treatment options that often results in amputations.
Sylvester Researchers Develop Predictive Model to Guide Immunotherapy for Lung Cancer Patients 01.19.2018
Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed a predictive model that can help guide immunotherapy for patients with advanced non-small cell lung cancer.
Often referred to as the “silent killer,” ovarian cancer does not become symptomatic for many women until a late stage of the disease. So any advance that shifts detection earlier, and allows physicians to intervene when survival remains potentially longer, can be welcome news. Sylvester researcher Brian Slomovitz, M.D., and colleagues are conducting a biomarker study to improve early detection, and survival.
In hopes of making a difference for children suffering from sickle cell anemia, Shanette Daniels, a family advocate for the Early Learning Coalition of Miami-Dade/Monroe, created an event she hopes will become an annual tradition. Daniels and her sister, Toni Knight, came up with the idea for a walk-a-thon early in 2017.
Ioan Opris, Ph.D., associate scientist at The Miami Project to Cure Paralysis at the University of Miami Miller School of Medicine, has edited and published The Physics of the Mind and Brain Disorders (Springer), a groundbreaking book about the physics of the mind that explores recent advances in the understanding of brain structure, functionality and cognitive disorders based on fundamental principles of physics.
A University of Miami Miller School of Medicine researcher is taking a prominent role in a high-priority National Institutes of Health research consortium designed to identify promising new targets for drug development. It’s part genomics, part big data, and all about driving discoveries that could someday translate to new treatments for cancer, neurological diseases, and other conditions, said Stephan Schürer, Ph.D.
An internationally renowned oral and maxillofacial surgeon with UHealth – the University of Miami Health System and the Miller School of Medicine is leading a collaborative study to determine the cause of a 14-year-old Cuban boy’s unusual facial tumor and underlying bone disorder.
If you build it, the data will not only come, it will be standardized, accessible and reusable by researchers around the world. With this in mind, the National Institutes of Health is creating its Data Commons initiative and invited University of Miami investigators to contribute their expertise. "There is a big effort at the NIH now to bring biomedical research into the data science era," said Stephan Schürer, Ph.D.
Researchers from Sylvester Comprehensive Cancer Center and Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine have uncovered evidence that genomic aberrations in uveal melanoma that lead to metastasis may occur far earlier in tumor evolution than previously believed. The findings fundamentally change the thinking about how this eye cancer progresses.